Our lead program is azelaprag,
a potential first-in-class oral therapeutic
for obesity, followed by several earlier-stage metabolic programs
Program
Mechanism of Action
Route of administration
Indication
Status
Azelaprag
(BGE-105)
(BGE-105)
APJ agonist
Oral
IV
Obesity (tirzepatide co-administration)
Acute muscle atrophy
Ph 2
Planning in process
Discoverу
Lead Op
IND-enabling
Ph 1
Ph 2
Ph 3
Pilot study
Planning in process
Discoverу
Lead Op
IND-enabling
Ph 1
Ph 2
Ph 3
BGE-100
NLRP3 inhibitor
Oral
Neuroinflammation
IND-enabling
Discoverу
Lead Op
IND-enabling
Ph 1
Ph 2
Ph 3
Discovery
Undisclosed metabolic
-
-
Disc.
Discoverу
Lead Op
IND-enabling
Ph 1
Ph 2
Ph 3
Program
Azelaprag
(BGE-105) oral
Azelaprag
(BGE-105) IV
Mechanism of Action
APJ agonist
Route of administration
Oral
Indication
Obesity (tirzepatide co-administration)
Status
Ph 2
Planning in process
Discoverу
Lead Op
IND-enabling
Ph 1
Ph 2
Ph 3
Mechanism of Action
APJ agonist
Route of administration
IV
Indication
Acute muscle atrophy
Status
Pilot study
Planning in process
Discoverу
Lead Op
IND-enabling
Ph 1
Ph 2
Ph 3
Program
BGE-100
-
Mechanism of Action
NLRP3 inhibitor
Route of administration
Oral
Indication
Neuroinflammation
Status
IND-enabling
Discoverу
Lead Op
IND-enabling
Ph 1
Ph 2
Ph 3
Program
Discovery
-
Mechanism of Action
Undisclosed metabolic
Route of administration
-
Indication
-
Status
Disc.
Discoverу
Lead Op
IND-enabling
Ph 1
Ph 2
Ph 3
